Markets:

Overview

News

Currencies

International

Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.84 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings ↗

May 09, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 09, 2023

Via Benzinga

Crude Oil Down 1%; Under Armour Earnings Top Views ↗

May 09, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 50 points on Tuesday. The Dow traded down 0.07% to 33,593.48 while the NASDAQ fell 0.52% to 12,193.35. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 09, 2023

Via Benzinga

Expert Ratings for Enanta Pharma ↗

May 09, 2023

Via Benzinga

Enanta Pharma Earnings Preview ↗

May 05, 2023

Via Benzinga

Expert Ratings for Enanta Pharma ↗

March 22, 2023

Via Benzinga

Enanta Pharmaceuticals's Earnings: A Preview ↗

February 06, 2023

Via Benzinga

Earnings Outlook For Enanta Pharmaceuticals ↗

November 18, 2022

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

10 Companies That Had Tons of Money in SVB When It Collapsed ↗

March 13, 2023

Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB.

Via InvestorPlace

Recap: Enanta Pharmaceuticals Q3 Earnings ↗

August 08, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Enanta Pharmaceuticals ↗

July 01, 2022

Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for Enanta Pharmaceuticals ↗

June 01, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Earnings Scheduled For November 21, 2022 ↗

November 21, 2022

Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million.

Via Benzinga

What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

August 01, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study ↗

July 29, 2022

Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants ↗

July 29, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a...

Via Benzinga

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗

June 28, 2022

Via Benzinga

Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid ↗

June 22, 2022

Another company says it invented the technology behind the pill first.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 ↗

July 06, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗

June 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint ↗

May 18, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

May 10, 2022

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.

Via Benzinga

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial ↗

February 16, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

Headline News about Enanta Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today